Background of study: Chemotherapy-induced peripheral neuropathy (CIPN) is an adverse effect of many chemotherapeutic agents and a major cause of pain in cancer survivors. Severe acute CIPN may require chemotherapy dose reduction or cessation. There is no effective CIPN prevention strategy; treatment of established chronic CIPN is limited, and risk factors of CIPN are also elusive. Objectives of the study: To identify the clinical& genetic risk factors of chemotherapy induced peripheral neuropathy in adult population. Research Methodology: The systematic review was used to identify studies reporting the risk factors of CIPN, searched Delnet, Remote XS (PGIMER), Ebsco, Willey online library, Medline, PubMed, and Web of Knowledge for relevant references and used random-effects meta-regression. Study quality assessed by using the CONSORT and STROBE guidelines, and PRISMA guidance. Conclusion and Results: This systematic review included 133 studies with data from 12,378 patients in the meta-analysis. A qualitative summary of factors reported to alter the risk of CIPN provided. Out of 133, sixty eight studies explained various risk factors contributing to CIPN. Genetic risk factors were reported in 19 studies. Clinical risk factors, identified in 29 studies, included neuropathy at baseline, cumulative dose, double-crush syndrome, abnormal creatinine clearance, LDH variation, EEG changes, specific sensory changes during chemotherapy, and persistent muscle and joint pains.
